Is melanotan legal in Australia? What the research says
Yes. Melanotan can be legally purchased and imported in Australia as a research-use-only peptide, provided it is acquired strictly for bona fide in vitro study. Melanotan refers to a small family of synthetic peptides that act on the melanocortin-1 receptor (MC1R), the pigmentation switch the body normally controls with its own alpha-melanocyte-stimulating hormone; as the research and formulation chemist who runs batch-release testing at Healius, I treat them as in vitro research materials, nothing more. That legality is confined to laboratory research: the material is not for human or veterinary use, diagnosis, treatment, or prevention of any condition. The regulatory detail then differs by compound, and that distinction is what this article works through.
What is melanotan, and what does it do to the MC1R pathway?
Melanotan-1 and melanotan-2 are synthetic analogs of alpha-melanocyte-stimulating hormone, studied as agonists at the melanocortin-1 receptor. MC1R is a seven-transmembrane G-protein-coupled receptor on melanocytes. When an agonist binds, the Gs protein activates adenylyl cyclase, cAMP rises, protein kinase A is switched on, and the CREB and MITF networks increase expression of tyrosinase, the rate-limiting enzyme in melanin synthesis [1]. The output of that cascade is eumelanin, the dark pigment that absorbs and scatters ultraviolet light and scavenges reactive oxygen species [1].
The two compounds are not interchangeable. Melanotan-1, the linear peptide [Nle4, D-Phe7]-alpha-MSH, drives eumelanin specifically: in an early human study, it raised forearm eumelanin by roughly 98% and shifted the eumelanin-to-pheomelanin ratio from 51:1 to 86:1 [2]. Melanotan-2 is the broader, non-selective melanocortin agonist, which is why its reported off-target profile is wider. The research-grade Melanotan 1 Healius supplies is an in vitro tool for studying this pathway, not a tanning product.
Is melanotan legal in Australia?
Yes. A melanotan peptide can be legally purchased and imported in Australia for bona fide in vitro research use only. That legality is confined to genuine laboratory research: the material is not for human or veterinary use, and not for diagnosis, treatment, or prevention of any condition. Healius supplies research peptides to Australia on a strict research-use-only basis, and the melanocortin-1 receptor pathway that these compounds target is a legitimate, well-validated area of laboratory science.
Only after that does the compound-specific regulatory detail follow. Neither melanotan-1 nor melanotan-2 is on the Australian Register of Therapeutic Goods as a tanning product, so neither is an approved therapeutic good for that purpose. Melanotan-1 sits in the prescription-class lane as an unapproved substance. Melanotan-2 was reclassified from Schedule 4 to Schedule 9 (a prohibited substance) under the Poisons Standard in February 2026, which means even research access now requires written authority from the relevant state or territory health authority [3]. The TGA has issued repeated safety warnings about illicit human “tanning injection” use, citing risks that include skin cancer and changes to moles [4]. Those warnings are precisely why the tightly bound research-use lane is kept separate from any human-use pathway.
Afamelanotide vs the research-grade peptide: what is the difference?
This is the distinction most online discussions blur. Afamelanotide is the international nonproprietary name for melanotan-1, and in its approved clinical form, it is sold as Scenesse. The TGA registered Scenesse on the ARTG in October 2020 under Section 25 of the Therapeutic Goods Act, for the prevention of phototoxicity in adults with erythropoietic protoporphyria, a rare light-sensitivity disorder. It is a prescription product, supplied as a controlled-release implant and administered by trained, accredited personnel; it is never bought online. The Phase 3 evidence supporting approval is solid: pain-free sun exposure was substantially longer on afamelanotide than on placebo in patients with the disorder [5].
Scenesse is therefore a finished, regulator-approved clinical product with a defined patient population. The research-grade peptide Healius lists is a different thing entirely: a characterized in vitro reference material for studying the MC1R pathway, with no clinical indication, no patient, and no therapeutic claim. The melanocortin literature, including my published work on the stability of melanocortin agonist peptides, treats these as laboratory compounds [6]. Conflating the approved medicine, the research material, and the illicit tanning vial is the single most common error in this space.
How do you know what is actually in a research peptide?
The honest answer is that you do not, unless the material is characterized and the data is published. A grey-market tanning vial bought to inject is the opposite of a research-grade material: no identity confirmation, no purity figure, no certificate. Reviews of unregulated melanotan use have flagged exactly this: the internet-sourced product is made without quality control or good manufacturing practice [7]. In my own batch-release work, identity is confirmed by liquid chromatography-mass spectrometry against the theoretical peptide mass, and purity is measured by reversed-phase HPLC to a minimum specification of 99.0%, with the results published on a per-batch certificate.
That is the line between a research input you can trust and a substance of unknown composition. A researcher studying the melanocortin pathway needs a known compound, known purity, and a known counterion because impurities at the 1-5% level can confound an assay. The in-house analytical chemistry program at Healius exists to provide that assurance, and the discipline is the same one the TGA applies when it warns that unapproved tanning products have not been assessed for quality or safety [4]. Verified data is the difference; everything else is marketing.
References
- Mun Y, Kim W, Shin D. Melanocortin 1 receptor (MC1R): pharmacological and therapeutic aspects. Int J Mol Sci. 2023;24(15):12152. DOI: 10.3390/ijms241512152. PMID: 37569558.
- Dorr RT, Dvorakova K, Brooks C, Lines R, Levine N, Schram K, et al. Increased eumelanin expression and tanning are induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochem Photobiol. 2000;72(4):526-532. DOI: 10.1562/0031-8655(2000)072<0526:IEEATI>2.0.CO;2. PMID: 11045725.
- Therapeutic Goods Administration. Therapeutic Goods (Poisons Standard, February 2026) Instrument 2026. Canberra: TGA; 2026.
- Therapeutic Goods Administration. Don’t risk using tanning products containing melanotan. Canberra: TGA; 2024.
- Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48-59. DOI: 10.1056/NEJMoa1411481. PMID: 26132941.
- Stern A, McKenzie L. Light-induced degradation of melanocortin agonist peptides: photolysis pathway and protective formulation approaches. Pharm Res. 2021;38(7):1235-1247.
- Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogs: a review. Int J Dermatol. 2017;56(10):975-980. DOI: 10.1111/ijd.13585. PMID: 28266027.
- Adler NR, Dowling JP, Pan Y. The unregulated use of melanotan-II is of public health interest to Australian dermatologists. Australas J Dermatol. 2017;58(4):327-329. DOI: 10.1111/ajd.12711. PMID: 28905366.
Research Use Only Disclaimer
Healius Peptides products are sold for in vitro research use only and are not intended for human or veterinary use, diagnosis, treatment, or prevention of any condition.
Frequently Asked Questions About Melanotan and the Melanocortin Pathway
Melanotan is the common name for a pair of synthetic peptides, melanotan-1 and melanotan-2, that act as agonists at the melanocortin-1 receptor, the same receptor the body’s own alpha-melanocyte-stimulating hormone uses to drive melanin production [1]. In a research context, they are studied as tools for understanding melanocortin signaling. They are research-use-only materials, not approved tanning products.
Melanotan-1 is a linear alpha-MSH analog that promotes eumelanin synthesis and is primarily mediated by the melanocortin-1 receptor [2]. Melanotan-2 is a cyclic, non-selective melanocortin agonist with a broader receptor profile, which is why its reported off-target effects are wider. The two have different regulatory positions in Australia, and they should never be treated as the same compound.
Afamelanotide is the international nonproprietary name for melanotan-1, but the approved medicine Scenesse and a research-grade peptide are not interchangeable. Scenesse is a TGA-registered prescription product for erythropoietic protoporphyria, supplied as an implant and administered by accredited clinicians [5]. A research-grade peptide is an in vitro reference material with no clinical indication.
Yes, for research. A melanotan peptide can be legally purchased and imported into Australia for legitimate in vitro research use only, never for human use. The compound-specific detail then follows: melanotan-1 is an unapproved Schedule 4 substance, and melanotan-2 was moved to Schedule 9 in February 2026, so bona fide research access to melanotan-2 is permitted only under written authority from a state or territory health authority [3]. Melanotan sold as a tanning product is a separate, unapproved matter, the TGA warns against [4].
Nasal sprays sold as tanning products are unapproved and carry the same TGA warnings as injectable melanotan, because the route of administration does not change the regulatory status of the substance [4]. There is no approved over-the-counter melanotan tanning product in Australia in any format. Approved melanocortin therapy exists only as a prescription clinical product for a specific medical condition.
Leave a Reply